Skip to content

Human Repeat Insult Patch Testing

Evaluation of the Cumulative Irritation and Potential for Sensitization of Test Products in Healthy Adult Human Subjects by Repeat Insult Patch Testing

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/03/024322
Enrollment
200
Registered
2020-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: 1 Lotion 2 Wipes 3 Soap 4 Soap 5 Soap 6 Lotion 7 body wash 8 Lotion 9 body wash 10 body wash : 1 0.04 ml of product will be applied and occluded. 2 Neat 3 0.04 ml of product will be app

Sponsors

The Himalaya Drug Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Age 18 to 65 years both inclusive at the time of consent 2 Sex Males and non-pregnant/non-lactating females preferably equal numbers of males and females 3 Females of childbearing potential must have a negative urine pregnancy test performed on Day 01 prior to patch application 4 Subjects who do not have any previous history of adverse skin conditions and are not under any medication likely to interfere with the results 5 Subjects in good general health as determined by the Investigator on the basis of medical history 6 Subjects willing and able to follow the study directions, to participate in the study returning for all specified visits 7 Subjects must be able to understand and provide written informed consent to participate in the study 8 Subjects willing to take bath using the same soap or cleansers during the study period. 9 Subjects willing to refrain from vigorous physical exercise during the study period.

Exclusion criteria

Exclusion criteria: 1) Subjects having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading. 2) Medication which may affect skin response and/or past medical history. 3) Subjects having history of diabetes. 4) Subjects have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months. 5) Subjects suffering from any active clinically significant skin diseases which may contraindicate. 6) Subjects having history of any skin diseases including eczema, atopic dermatitis or active cancer. 7) Participation in any patch test for irritation or sensitization within the last four weeks. 8) Subjects having history of asthma or COPD (Chronic obstructive pulmonary disease). 9) Subjects with Self-reported Immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematous. 10) Individual who has a medical condition or is taking or has taken a medication which, in the Investigatorâ??s judgment, makes the subject ineligible or places the subject at undue risk. 11) Subject with known allergy or sensitization to medical adhesives, bandages. 12) Subjects has participation in a clinical drug study or skin irritation/sensitization study during the 30 days preceding the initial patch application in this study. 13) Subject reports a history of skin sensitivity to shampoos and detergents or a known hypersensitivity and/or sensitization to medical adhesives. 14) Subjects reports use of systemic or topical antihistamines (at any site) or uses of topical drugs at patch site(s) within 72 hours prior to patch application. 15) Participation in other patch study simultaneously. 16) Use of any: i. Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application. ii. Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. iii. Systemic or topical corticosteroids at patch site within four (4) weeks of Test Product application (steroidal nose drops and/or eye drops are permitted). iv. Topical drugs used at application site.

Design outcomes

Primary

MeasureTime frame
1 To determine the cumulative irritation potential of the test product 2 To determine sensitization potential of the product.Timepoint: 1 To determine the cumulative irritation potential of the test product 2 Induction Phase: Visit 3, Visit 5, Visit 7, Visit 9, Visit 11, Visit 13, Visit 15, Visit 17, Visit 19. Challenge Phase: Visit 22, Visit 23, visit 24, Visit 25 and Visit 26

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactMs Maheshvari Patel

Cliantha Research

nkpatel@cliantha.com9909013286

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026